Literature DB >> 30524601

Repeated intra-stent thrombus formation in a patient with acute coronary syndrome due to poor responsiveness to clopidogrel may be associated with cytochrome P-450 2C19*2 polymorphism.

Masamichi Iwasaki1, Takahiro Sawada1, Toshiro Shinke2, Hiroshi Okamoto1, Su-Sik Kim1, Junya Shite2, Ken-Ichi Hirata2, Mitsuhiro Yokoyama1.   

Abstract

A drug-eluting stent was implanted at the culprit lesion in a 65-year-old man with acute coronary syndrome. Nine days after the procedure, he suffered stent thrombosis, and a bare-metal stent was subsequently implanted. Twelve days after this second procedure, a follow-up angiogram showed a newly emerged thrombus at the site of stent implantation. Although the patient had continued dual anti-platelet therapy with aspirin and clopidogrel since the first procedure, platelet optical aggregation test showed no inhibition of aggregation. Further, genetic analysis revealed him to be homozygous for the CYP2C19*2 polymorphism. This case suggests that the mechanism of stent thrombosis, while multi-factorial, is affected greatly by crossover of poor responsiveness to clopidogrel due to the CYP2C19*2 polymorphism.

Entities:  

Keywords:  Clopidogrel; Cytochrome P450 2C19*2 polymorphism; Poor responsiveness; Sub-acute stent thrombosis

Year:  2011        PMID: 30524601      PMCID: PMC6265030          DOI: 10.1016/j.jccase.2011.02.003

Source DB:  PubMed          Journal:  J Cardiol Cases        ISSN: 1878-5409


  14 in total

1.  Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials.

Authors:  D E Cutlip; D S Baim; K K Ho; J J Popma; A J Lansky; D J Cohen; J P Carrozza; M S Chauhan; O Rodriguez; R E Kuntz
Journal:  Circulation       Date:  2001-04-17       Impact factor: 29.690

Review 2.  Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding.

Authors:  Shinya Goto
Journal:  Atheroscler Suppl       Date:  2005-11-04       Impact factor: 3.235

3.  Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects.

Authors:  Jean-Sébastien Hulot; Alessandra Bura; Eric Villard; Michel Azizi; Véronique Remones; Catherine Goyenvalle; Martine Aiach; Philippe Lechat; Pascale Gaussem
Journal:  Blood       Date:  2006-06-13       Impact factor: 22.113

4.  Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study.

Authors:  Paul A Gurbel; Kevin P Bliden; Waiel Samara; Jason A Yoho; Kevin Hayes; Mulugeta Z Fissha; Udaya S Tantry
Journal:  J Am Coll Cardiol       Date:  2005-10-19       Impact factor: 24.094

5.  Early stent thrombosis in patients with acute coronary syndromes treated with drug-eluting and bare metal stents: the Acute Catheterization and Urgent Intervention Triage Strategy trial.

Authors:  Jiro Aoki; Alexandra J Lansky; Roxana Mehran; Jeffery Moses; Michel E Bertrand; Brent T McLaurin; David A Cox; A Michael Lincoff; E Magnus Ohman; Harvey D White; Helen Parise; Martin B Leon; Gregg W Stone
Journal:  Circulation       Date:  2009-01-26       Impact factor: 29.690

6.  Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis.

Authors:  Betti Giusti; Anna Maria Gori; Rossella Marcucci; Claudia Saracini; Ilaria Sestini; Rita Paniccia; Piergiovanni Buonamici; David Antoniucci; Rosanna Abbate; Gian Franco Gensini
Journal:  Am J Cardiol       Date:  2009-01-24       Impact factor: 2.778

7.  Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.

Authors:  Dietmar Trenk; Willibald Hochholzer; Martin F Fromm; Ligia-Emilia Chialda; Andreas Pahl; Christian M Valina; Christian Stratz; Peter Schmiebusch; Hans-Peter Bestehorn; Heinz Joachim Büttner; Franz-Josef Neumann
Journal:  J Am Coll Cardiol       Date:  2008-05-20       Impact factor: 24.094

8.  Cytochrome p-450 polymorphisms and response to clopidogrel.

Authors:  Jessica L Mega; Sandra L Close; Stephen D Wiviott; Lei Shen; Richard D Hockett; John T Brandt; Joseph R Walker; Elliott M Antman; William Macias; Eugene Braunwald; Marc S Sabatine
Journal:  N Engl J Med       Date:  2008-12-22       Impact factor: 91.245

9.  Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation.

Authors:  Takeshi Kimura; Takeshi Morimoto; Yoshihisa Nakagawa; Toshihiro Tamura; Kazushige Kadota; Hitoshi Yasumoto; Hideo Nishikawa; Yoshikazu Hiasa; Toshiya Muramatsu; Taiichiro Meguro; Naoto Inoue; Hidehiko Honda; Yasuhiko Hayashi; Shunichi Miyazaki; Shigeru Oshima; Takashi Honda; Nobuo Shiode; Masanobu Namura; Takahito Sone; Masakiyo Nobuyoshi; Toru Kita; Kazuaki Mitsudo
Journal:  Circulation       Date:  2009-02-09       Impact factor: 29.690

10.  Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.

Authors:  Shlomi Matetzky; Boris Shenkman; Victor Guetta; Michael Shechter; Roy Beinart; Roy Bienart; Ilan Goldenberg; Ilya Novikov; Hanna Pres; Naphtali Savion; David Varon; Hanoch Hod
Journal:  Circulation       Date:  2004-06-07       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.